Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

9.240 +0.160 (+1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,817,618
Open 9.070
Bid (Size) 7.150 (1)
Ask (Size) 9.240 (3)
Prev. Close 9.080
Today's Range 8.690 - 9.430
52wk Range 4.980 - 65.33
Shares Outstanding 147,693,858
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
 
Via Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease. 
Via Benzinga

Performance

YTD
-46.15%
-46.15%
1 Month
+39.37%
+39.37%
3 Month
-10.81%
-10.81%
6 Month
-19.79%
-19.79%
1 Year
-84.47%
-84.47%

More News

Read More
89 Biggest Movers From Friday
Via Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
Via Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
Via Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
Via Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Via Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
Via Benzinga
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
Via Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Via Benzinga
What 6 Analyst Ratings Have To Say About BridgeBio Pharma
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
Via Benzinga
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder
Via Benzinga
Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications
Via Benzinga
Insider Weekends: Co-Founder Of EverQuote Acquires $1.45 Million Worth Of Stock
Via Benzinga
BZ Chart Of The Day: BridgeBio Pharma Teaches Traders Harsh Lesson
Via Benzinga
40 Biggest Movers From Friday
Via Benzinga
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Via Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.